Internal Linking Suggestions

• BRICS+ Expansion
• India–Africa Trade Lanes
• Digital Health Transformation

From Generics to Innovation

India has long been known as the ‘pharmacy of the world’, supplying affordable
generics globally. Now, Asia and Africa are expanding beyond generics toward
vaccine research, biologics, and API (Active Pharmaceutical Ingredient) manufacturing
to reduce import dependence.

New Capacity Building

Recent milestones illustrate this shift toward innovation + capacity building:

• Africa: first mRNA vaccine plant in Senegal
• India: PLI (Production-Linked Incentive) schemes for pharma R&D
• ASEAN: biotech clusters accelerating research and production

Key Challenges

Despite progress, several obstacles remain:

• Regulatory harmonization across regions
• R&D talent shortages
• Intellectual property disputes
• Supply chain vulnerabilities for raw materials

Yet, the COVID-19 pandemic underscored the strategic necessity
of local vaccine and drug manufacturing.

The Future of Pharma

Public-private partnerships, cross-border research collaborations,
and digital clinical trial platforms are now shaping the future pharma map.

By 2030, Africa and Asia could meet much of their own vaccine and essential
drug demand domestically—reducing dependency on Western suppliers and strengthening
health security.